1. Sweden Stocks

  2. •

    Health technology

  3. •

    Medical specialties
Arcoma AB

Arcoma AB

SSTO:ARCOMA
8.00
SEK
+0.22
(+2.83%)
0.18EPS
49.54P/E
127.63MMarket Cap
Oct 22Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.25
1,504.48
11.85
9.87
7.87
9.45
10.57
9.22
9.05
9.48
12.36
11.89
9.14
9.18
Basic EPS, GAAP
-0.16
10.54
-0.62
-1.13
-0.84
-0.13
0.52
0.11
-0.58
0.14
0.19
0.85
0.35
0.18
Free Cash Flow per Basic Share
-0.24
-72.48
-0.95
-0.54
-1.03
-0.07
- -
-0.38
-0.47
-0.33
1.26
0.91
0.92
0.99
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
0.08
481.31
4.82
3.61
3.23
3.09
3.57
3.92
3.37
3.48
3.69
4.5
5.22
5.3
Tangible Book Value per Share
-0.14
110.8
1.92
1.42
1.71
1.92
1.87
1.6
1.32
1.61
2.22
3.1
4.05
4.14
Basic Weighted Avg Shares
87
- -
10
10
12
13
13
13
13
13
13
13
14
14
Sales/Revenue/Turnover
108
130
123
102
92
119
134
117
117
125
163
157
131
129
Operating Margin (%)
-11.27
3.01
-5.03
-12.43
-10.88
-0.32
6.81
4.13
-6.36
2.5
2.86
8.71
4.77
2.28
Depreciation Expense
5
7
8
9
6
6
4
3
6
7
8
8
7
6
Net Income, GAAP
-14
1
-6
-12
-10
-2
7
1
-7
2
3
11
5
3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
25.65
21.91
- -
10.33
18.19
18.8
20.23
19.81
Profit Margin (%)
-12.87
0.7
-5.23
-11.41
-10.69
-1.33
4.94
1.16
-6.38
1.52
1.57
7.13
3.85
1.96
Working Capital
6
6
16
8
14
17
17
16
10
17
23
36
55
56
LT Debt
17
2
3
2
1
1
- -
3
2
4
2
- -
- -
- -
Total Equity
7
42
50
37
41
39
45
50
44
46
49
59
75
76
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
12.91
4.6
- -
4.26
6.17
19.82
7.42
3.42
Return on Capital (%)
- -
- -
- -
- -
- -
- -
13.18
3
- -
4.12
6
20.36
7.64
3.81
Return on Common Equity (%)
-89.24
3.75
-14.07
-26.69
-25.12
-3.97
15.7
2.88
-15.97
4.23
5.42
20.7
7.5
3.68

Capital Structure

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
14
14
14
Market Capitalization
105
114
128

Working Capital

SEK

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
77
82
80
Cash, Cash Equivalents & STI
35
34
31
Accounts Receivable, Net
13
18
21
Inventories
24
26
24
Total Current Liabilities
22
26
24
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

SEK

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
5.21%
9.4%
25.94%
Free Cash Flow
1,661.9%
-100.73%
8.56%
Net Income, GAAP
-107.22%
-91.42%
-55%
Sales/Revenue/Turnover
1.91%
3.3%
-16.59%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
46
42
32
37
157
2025
35
31
- -
35
131
2026
31
32
- -
- -
- -

Quarterly Earnings Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.27
0.23
0.14
0.2
0.85
2025
0.16
- -
- -
0.1
0.35
2026
0.06
0.02
- -
- -
- -

Quarterly Dividends Per Share

SEK

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Leire Mattias
Full Time Employees
31
Sector
Health technology
Industry
Medical specialties
Address
AnnavAegen 1 Växjö KR Sweden 352 46
IPO Date
Nov 14, 2014
Website
arcoma.se
Similar Companies
Intuitive Surgical, Inc. (NASDAQ:ISRG)
Boston Scientific Corporation (NYSE:BSX)
Thermo Fisher Scientific Inc (NYSE:TMO)
Illumina, Inc. (NASDAQ:ILMN)
Abbott Laboratories (NYSE:ABT)
GRAIL, Inc. (NASDAQ:GRAL)
Business
Arcoma AB develops, produces, and provides complete digital radiography and radiology solutions globally, specializing in advanced digital X-ray systems that combine the latest imaging technology with technically advanced motorized positioning and ergonomic Scandinavian design. Its product portfolio includes digital X-ray systems such as the Precision series with autopositioning technology, the Intuition system featuring lightweight versatile design and auto-tracking, and ceiling suspensions optimized for high patient throughput and clinical workflow efficiency. The company serves hospitals, clinics, and imaging centers through OEM partners including Canon and Konica Minolta, as well as local distributors, with over 3,500 installations worldwide. Founded in 1989 and headquartered in Uppsala, Sweden, Arcoma focuses on patient-centric care by maximizing comfort and ease of use for radiologists and patients. In the last two years, Arcoma has notably completed a directed share issue raising approximately SEK 11.0 million (~EUR 1 million) led by Eiffel Investment Group, which became one of the company's largest shareholders, strengthening Arcoma's financial position and accelerating its growth strategy. The company plans to use the proceeds to expand sales resources, enhance product development and innovation, and actively pursue an acquisition strategy to consolidate its market position. Additionally, Arcoma won a significant procurement contract in Finland for up to six Precision i5 systems supplied to the HUS Medical Imaging Center, reflecting expanding operations within the Nordic region. These developments support Arcoma’s focus on improving profitability, market presence, and long-term value creation in the digital radiology industry. Arcoma operates primarily in the healthcare technology sector, targeting medical facilities requiring state-of-the-art digital imaging systems for radiology diagnostics. The company’s offerings are recognized for combining advanced digital imaging with specialized positioning technology, enabling efficient workflow and high patient throughput. Its strategic alliances with OEM partners and recent financial strengthening reinforce its position within international markets, particularly in Europe and North America. Arcoma’s business model leverages innovation, expansion, and partnerships to sustain its leadership in digital radiography since its founding and continued operations from Sweden.